

S1 Table. Summary of patient characteristics after adjustment with inverse probability of treatment weighting

Characteristic	RFA (n=178)	SBRT (n=44)	Unweighted SMD	Weighted SMD
Age (yr)				
≤ 70	144 (80.9)	36 (81.8)	0.024	0.056
> 70	34 (19.1)	8 (18.2)		
Sex				
Male	130 (73.0)	31 (70.5)	-0.057	0.030
Female	38 (27.0)	13 (29.6)		
Timing of liver metastasis				
Synchronous	62 (34.8)	24 (54.6)	0.405	-0.001
Metachronous	116 (65.2)	20 (45.5)		
Pre-treatment systemic therapy				
No	39 (21.9)	6 (13.6)	-0.218	0.008
Yes	139 (78.1)	38 (86.4)		
Post-treatment systemic therapy				
No	46 (25.8)	14 (31.8)	0.132	0.047
Yes	132 (74.2)	30 (68.2)		
CEA (ng/mL)				
< 6	137 (77.0)	31 (70.5)	-0.148	-0.043
≥ 6	41 (23.0)	13 (29.6)		
No. of liver metastasis				
1	120 (67.4)	30 (68.2)	0.016	-0.029
≥ 2	58 (32.6)	14 (31.8)		
Stage				
≤ II	41 (23.0)	8 (18.2)	-0.120	-0.038
> II	137 (77.0)	36 (81.8)		
Difficult location				
No	70 (39.3)	4 (9.1)	-0.754	0.001
Yes	108 (60.7)	40 (90.9)		

Values are presented as number (%). CEA, carcinoembryonic antigen; RFA, radiofrequency ablation; SBRT, stereotactic body radiation therapy; SMD, standardized mean difference.